Neuromuscular Disorders
Research activity centres on generalized myasthenia gravis, ocular myasthenia gravis, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, amyotrophic lateral sclerosis, and congenital myasthenic syndromes, with additional interest in pediatric and adult forms of these conditions.
- Myasthenia gravis
- Chronic inflammatory demyelinating polyneuropathy
- Amyotrophic lateral sclerosis
Trials also extend to AChR-antibody positive and seronegative disease subtypes, reflecting broad involvement across autoimmune neuromuscular weakness.
Autoimmune Thrombocytopenia
The sponsor funds studies in primary immune thrombocytopenia and chronic immune thrombocytopenia, including work that spans adult and adolescent populations.
- Primary immune thrombocytopenia
- Chronic immune thrombocytopenia
- Immune-mediated platelet disorders
These programs focus on autoimmune platelet destruction and persistent bleeding risk associated with reduced platelet counts.
Connective Tissue and Systemic Autoimmune Disease
Clinical research includes primary Sjögren’s syndrome, systemic sclerosis, idiopathic inflammatory myopathy, dermatomyositis, and related myositis syndromes.
- Primary Sjögren’s syndrome
- Systemic sclerosis
- Dermatomyositis
Additional activity covers active idiopathic inflammatory myopathy and broader systemic autoimmune manifestations affecting muscle, skin, and exocrine glands.
Dermatologic Autoimmunity and Thyroid-Related Eye Disease
Studies address bullous pemphigoid and thyroid eye disease, with attention to immune-mediated skin blistering and orbital inflammation.
- Bullous pemphigoid
- Thyroid eye disease
- Autoimmune skin disorders
These areas reflect interest in disorders driven by pathogenic autoantibodies and inflammatory tissue injury.
Transplantation and Renal Complications
Argenx also supports research in kidney transplantation, including antibody-mediated rejection and delayed graft function, alongside studies examining renal impairment and transplant-related immune complications.
- Antibody-mediated rejection
- Delayed graft function
- Renal impairment
These programs extend the sponsor’s clinical scope into post-transplant immune control and kidney graft outcomes.
